Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00002878. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective than combination chemotherapy alone in treating patients with relapsed or refractory multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma.
Study identification
- NCT ID
- NCT00002878
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- dexamethasone Drug
- doxorubicin hydrochloride Drug
- valspodar Drug
- vincristine sulfate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 1997 (Actual)
- Primary completion
- Apr 2003 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 15, 2023
Started 1997
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Cancer Center | La Jolla | California | 92093-0658 | — |
| UCSF Cancer Center and Cancer Research Institute | San Francisco | California | 94143-0128 | — |
| CCOP - Christiana Care Health Services | Wilmington | Delaware | 19899 | — |
| Walter Reed Army Medical Center | Washington D.C. | District of Columbia | 20307-5000 | — |
| CCOP - Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| Holden Comprehensive Cancer Center at The University of Iowa | Iowa City | Iowa | 52242-1009 | — |
| Marlene & Stewart Greenebaum Cancer Center, University of Maryland | Baltimore | Maryland | 21201 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| University of Minnesota Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Ellis Fischel Cancer Center - Columbia | Columbia | Missouri | 65203 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-3330 | — |
| CCOP - Southern Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756-0002 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| CCOP - North Shore University Hospital | Manhasset | New York | 11030 | — |
| Schneider Children's Hospital at North Shore | Manhasset | New York | 11030 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| New York Presbyterian Hospital - Cornell Campus | New York | New York | 10021 | — |
| Mount Sinai Medical Center, NY | New York | New York | 10029 | — |
| State University of New York - Upstate Medical University | Syracuse | New York | 13210 | — |
| CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. | Syracuse | New York | 13217 | — |
| Lineberger Comprehensive Cancer Center, UNC | Chapel Hill | North Carolina | 27599-7295 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| CCOP - Southeast Cancer Control Consortium | Winston-Salem | North Carolina | 27104-4241 | — |
| Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina | 27157-1082 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| University of Tennessee, Memphis Cancer Center | Memphis | Tennessee | 38103 | — |
| Vermont Cancer Center | Burlington | Vermont | 05401-3498 | — |
| MBCCOP - Massey Cancer Center | Richmond | Virginia | 23298-0037 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002878, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00002878 live on ClinicalTrials.gov.